Skip to content

Study · Animal study (in vivo) · rat · 2024

18 results

Preoperative abaloparatide plus zoledronate treatment accelerates femoral bone healing in rats following osteotomy.

Kataoka T, Tsubouchi Y, Takase R, Otsu T, Iwasaki T, Kataoka M, Kaku N

Journal of orthopaedic surgery (Hong Kong)1 Sept 2024Cited by 4 (Europe PMC)

PMID39403996 (opens in a new tab)DOI10.1177/10225536241293486 (opens in a new tab)PepBankPUB-39403996
Publisher pagePubMedAsk about this study
Jump to 18 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study18

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, abaloparatide accelerated callus formation compared with control.

    In plain wordsIn rats after bone surgery, abaloparatide accelerated callus formation compared with control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCallus formation
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, abaloparatide accelerated callus formation compared with zoledronate.

    In plain wordsIn rats after bone surgery, abaloparatide accelerated callus formation compared with zoledronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCallus formation
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    zoledronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, abaloparatide accelerated callus maturation compared with control.

    In plain wordsIn rats after bone surgery, abaloparatide accelerated callus maturation compared with control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCallus maturation
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, abaloparatide accelerated callus maturation compared with zoledronate.

    In plain wordsIn rats after bone surgery, abaloparatide accelerated callus maturation compared with zoledronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCallus maturation
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    zoledronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, abaloparatide accelerated fracture line closure compared with control.

    In plain wordsIn rats after bone surgery, abaloparatide accelerated fracture line closure compared with control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFracture line closure
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, abaloparatide accelerated fracture line closure compared with zoledronate.

    In plain wordsIn rats after bone surgery, abaloparatide accelerated fracture line closure compared with zoledronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFracture line closure
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    zoledronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, adding abaloparatide to zoledronate accelerated callus formation compared with zoledronate alone.

    In plain wordsIn rats, adding abaloparatide to zoledronate accelerated callus formation compared with zoledronate alone.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCallus formation
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    zoledronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, adding abaloparatide to zoledronate accelerated callus maturation compared with zoledronate alone.

    In plain wordsIn rats, adding abaloparatide to zoledronate accelerated callus maturation compared with zoledronate alone.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCallus maturation
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    zoledronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, adding abaloparatide to zoledronate accelerated fracture line closure compared with zoledronate alone.

    In plain wordsIn rats, adding abaloparatide to zoledronate accelerated fracture line closure compared with zoledronate alone.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFracture line closure
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    zoledronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats, adding abaloparatide to zoledronate increased contralateral trabecular BMD compared with zoledronate alone.

    In plain wordsIn rats, adding abaloparatide to zoledronate increased trabecular bone density compared with zoledronate alone.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseContralateral trabecular BMD
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    zoledronate alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Both trabecular and cortical bone mineral densities were also greater in contralateral femurs of the Abalo + ZA group compared to Abalo and ZA groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In rats, adding abaloparatide to zoledronate increased contralateral cortical BMD compared with zoledronate alone.

    In plain wordsIn rats, adding abaloparatide to zoledronate increased cortical bone density compared with zoledronate alone.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseContralateral cortical BMD
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    zoledronate alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg, 5 times per week · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Both trabecular and cortical bone mineral densities were also greater in contralateral femurs of the Abalo + ZA group compared to Abalo and ZA groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.

Studies that did not test the peptide alone7

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 12AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, abaloparatide plus zoledronate accelerated callus formation compared with control.

    In plain wordsIn rats, abaloparatide plus zoledronate accelerated callus formation compared with control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCallus formation
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    control
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 13AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, abaloparatide plus zoledronate accelerated callus maturation compared with control.

    In plain wordsIn rats, abaloparatide plus zoledronate accelerated callus maturation compared with control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCallus maturation
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    control
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  3. 14AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In rats after osteotomy, abaloparatide plus zoledronate accelerated fracture line closure compared with control.

    In plain wordsIn rats, abaloparatide plus zoledronate accelerated fracture line closure compared with control.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFracture line closure
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    control
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Soft X-ray imaging revealed accelerated callus formation, callus maturation, and fracture line closure in Abalo and Abalo + ZA groups compared to ZA and control groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  4. 15AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In rats, abaloparatide plus zoledronate increased contralateral cortical bone volume fraction compared with abaloparatide alone.

    In plain wordsIn rats, abaloparatide plus zoledronate increased cortical bone volume fraction compared with abaloparatide alone.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseContralateral cortical bone volume fraction
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    abaloparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Micro-CT demonstrated greater cortical bone and trabecular bone to total volume ratios in contralateral (left) femurs of the Abalo + ZA group compared to the Abalo group.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  5. 16AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In rats, abaloparatide plus zoledronate increased contralateral trabecular bone volume fraction compared with abaloparatide alone.

    In plain wordsIn rats, abaloparatide plus zoledronate increased trabecular bone volume fraction compared with abaloparatide alone.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseContralateral trabecular bone volume fraction
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    abaloparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Micro-CT demonstrated greater cortical bone and trabecular bone to total volume ratios in contralateral (left) femurs of the Abalo + ZA group compared to the Abalo group.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  6. 17AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In rats, abaloparatide plus zoledronate increased contralateral trabecular BMD compared with abaloparatide alone.

    In plain wordsIn rats, abaloparatide plus zoledronate increased trabecular bone density compared with abaloparatide alone.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseContralateral trabecular BMD
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    abaloparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Both trabecular and cortical bone mineral densities were also greater in contralateral femurs of the Abalo + ZA group compared to Abalo and ZA groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  7. 18AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome

    In rats, abaloparatide plus zoledronate increased contralateral cortical BMD compared with abaloparatide alone.

    In plain wordsIn rats, abaloparatide plus zoledronate increased cortical bone density compared with abaloparatide alone.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseContralateral cortical BMD
    Study

    ratn = 28

    Sprague-Dawley femoral osteotomy
    Comparator
    abaloparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Both trabecular and cortical bone mineral densities were also greater in contralateral femurs of the Abalo + ZA group compared to Abalo and ZA groups.
    2 context sentences
    Summary · context
    Nine-week-old male Sprague-Dawley rats were randomly divided into four groups (n = 14 per group): control, abaloparatide (Abalo, 30 μg/kg via subcutaneous injection [s.c.] 5 times per week for 6 weeks), zoledronate (ZA; 0.1 mg/kg via s.c., single dose), and Abalo + ZA.
    Summary · context
    At 2 and 4 weeks after osteotomy, both femurs were removed from seven rats per group for soft X-ray imaging to evaluate bone union and microcomputed tomography (micro-CT) for bone morphometric evaluation.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.